Evaluation of Cox2 expression in colorectal carcinoma in patients undergoing colectomy in Imam Khomeini Hospital of Ahvaz

Document Type : Original Article

Authors

1 Ahvaz jundishapur univercity of medical science , pathology department

2 dr

Abstract

Objective: The aim of this study was to evaluate the expression of COX2 protein in patients with colorectal carcinoma in order to better understand the pathophysiology and behavior of inflammatory factors in this disease.
Materials and Methods: In this cross-sectional descriptive study, tissue paraffin blocks of patients referring to Imam Khomeini teaching hospitals with pathological diagnosis of colorectal cancer were evaluated. Clinical and demographic data of patients were extracted from hospital records. Anti Cox2 monoclonal antibody was used for immunohistochemical staining.
Results: In this study, 31 patients with colorectal cancer (mean age 65.1 (range 33 to 89)) were evaluated. Most tumors had grade G2 (54.8%). Tumor stage pt3 was also seen in more than half of cases. Lymph node involvement was observed in 29% of cases. The mean staining area was 34.6% (range 2 to 78%). More than half of the patients showed moderate marker expression and 6.5% had a strong positive reaction. However, 16.1% of patients were negative for Cox2 marker. We have failed to find any significant correlation of stage, grade and lymph node involvement with Cox2 expression status.
Conclusion: The findings of this study indicate that more than 70% of colorectal malignant tissues express Cox2 marker. However, Cox2 marker expression had no significant association with pathologic variables such as tumor grade, stage and extent of metastasis to the surrounding lymph nodes.

Keywords

References

1-Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010;29(6):781-8.
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61(5):759-67
2-engauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396(6712):643-9.
3-Liu Y, Sun H, Hu M, Zhang Y, Chen S, Tighe S, Zhu Y. The role of cyclooxygenase-2 in colorectal carcinogenesis. Clinical colorectal cancer. 2017 Sep 1;16(3):165-72.
4-Stolfi C, De Simone V, Pallone F, Monteleone G. Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer. Int J Mol Sci 2013;14(9):17972-85.
5-Iwama T. NSAIDs and colorectal cancer prevention. J Gastroenterol 2009;44 Suppl 19:72-6.
6-Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P. Mechanisms underlying the growth inhibitory effects of the cyclooxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res 2005;7(4):R422-35.
7-Salimi M, Esfahani M, Habibzadeh N, Aslani HR, Amanzadeh A, Esfandiary M, et al. Change in nicotine-induced VEGF, PGE2 AND COX-2 expression following COX inhibition in human oral squamous cancer. J Environ Pathol Toxicol Oncol 2012;31(4):349-56.
8-Kumar BN, Rajput S, Dey KK, Parekh A, Das S, Mazumdar A, et al. Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling. BMC Cancer 2013;13:273.
9-Wu QB, Sun GP. Expression of COX-2 and HER-2 in colorectal cancer and their correlation. World Journal of Gastroenterology: WJG. 2015 May 28;21(20):6206.
10-Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T: Expression of cyclooxygenase-1 and −2 in human colorectal cancer. Cancer Res. 1995, 55: 3785-3789.
11-Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994, 107: 1183-1188.
12-Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K: Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterology. 2006, 12: 1336-1345
13-Brown JR, DuBois RN: COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol. 2005, 23: 2840-2855
14-Mehta S, Boddy A, Johnson T, Rhodes M: Systematic review: cyclo-oxygenase-2 in human oesophageal adenocarcinogenesis. Aliment Pharmacol Ther. 2006, 24: 1321-1331. 10.1111/j.1365-2036.2006.03119.x
15-Liu X, Li P, Zhang ST, You H, Jia JD, Yu ZL: COX-2 mRNA expression in esophageal squamous cell carcinoma (ESCC) and effect by NSAID. Dis Esophagus. 2008, 21: 9-14.
16-Li X, Kong L, Liao S, Lu J, Ma L, Long X. The expression and significance of feces cyclooxygensae-2 mRNA in colorectal cancer and colorectal adenomas. Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association. 2017 Jan;23(1):28
17-VEnkAtAChAlA S, RAjEndRAn M. Correlation of COX-2 Expression in Colorectal Carcinoma with Clinicopathological Features. Turkish Journal of Pathology. 2017 Sep 1;33(3):228-34.
18-Chen ZK, Ouyang ZT. Relationship between carcinoembryonic antigen and cyclooxygenase 2 expression and colorectal cancer. Ai zheng= Aizheng= Chinese journal of cancer. 2003 Feb;22(2):164-7.
Jundishapur Scientific Medical Journal
Volume 19, Issue 2 - Serial Number 125
May and June 2020
Pages 177-186

Files

History

  • Receive Date: 17 January 2020
  • Revise Date: 26 February 2020
  • Accept Date: 26 February 2020

Share

How to cite

Statistics